In:
Open Forum Infectious Diseases, Oxford University Press (OUP), Vol. 5, No. 11 ( 2018-11-01)
Kurzfassung:
Although the use of tenofovir alafenamide (TAF), a new prodrug of tenofovir, was safe and efficacious in clinical trials, real-world data from multimorbid individuals are scarce. Among 10 persons living with HIV with previous tenofovir disoproxil fumarate–induced nephrotoxicity, renal function remained stable, and proteinuria decreased in several patients after the switch to TAF.
Materialart:
Online-Ressource
ISSN:
2328-8957
Sprache:
Englisch
Verlag:
Oxford University Press (OUP)
Publikationsdatum:
2018
ZDB Id:
2757767-3